Guru P. Sonpavde MD
Genitourinary Oncology Director, Christopher K. Glanz Chair for Bladder Cancer Research, Assistant Director Phase I Clinical Research Unit, AdventHealth Cancer Institute, Orlando, FloridaDr. Guru Sonpavde, MD, is the Genitourinary Oncology Director at the AdventHealth Cancer Institute and the Christopher K. Glanz Chair for Bladder Cancer Research. He completed his fellowship in medical oncology and hematology at Indiana University. He leads multiple cutting-edge clinical trials studying novel immunotherapy and targeted drugs to treat urological cancers, particularly bladder cancer. He is the national or international principal investigator on multiple clinical trials for bladder cancer. He has also led translational projects and developed prognostic classifications and clinical endpoints focused on bladder cancer. He is a member of Southwest Oncology Group (SWOG) and the Bladder Cancer Task Force of the National Cancer Institute Genitourinary Cancers Steering Committee.
Disclosures
Dr. Sonpavde reports the following:
-
Advisory Board: BMS, Genentech, EMD Serono, Merck, Sanofi, Seattle Genetics/Astellas, Astrazeneca, Exelixis, Janssen, Bicycle Therapeutics, Pfizer, Gilead, Scholar Rock, G1 Therapeutics, Eli Lilly/Loxo Oncology, Infinity Pharmaceuticals, Lucence Health, IMV
-
Research Support: Sanofi (iaward), Astrazeneca, Gilead, Helsinn, Lucence, Predicine, BMS, EMD Serono, Jazz Therapeutics, Genecentric, Kure it, NCI (R21)
- Steering committee of studies: BMS, Bavarian Nordic, Seattle Genetics, QED, G1 Therapeutics (all unpaid), and Astrazeneca, EMD Serono, Debiopharm (paid)
- Data safety monitoring committee: Mereo
- Employment: Spouse employed by Myriad
- Writing/Editor fees: Uptodate, Editor of Elsevier Practice Update Bladder Cancer Center of Excellence
- Speaking fees: Physicians Education Resource (PER), Onclive, Research to Practice, Medscape, Cancer Network, Masters Lecture Series (MLS)
Recent Contributions to PracticeUpdate:
- Genitourinary Tumor Board: Bladder Cancer
- Adjuvant Nivolumab for High-Risk Muscle-Invasive Urothelial Carcinoma
- Key Takeaways From ESMO: Updates on Immunotherapy for Bladder Cancer
- An Overview of Chemotherapy Combinations in Urothelial Carcinoma
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
- Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin vs Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Muscle-Invasive Bladder Cancer
- Clinical Perspectives on New Data on Antibody-Drug Conjugates for Refractory Urothelial Cancer
- Enfortumab Vedotin-ejfv Improves OS Significantly in Previously Treated Locally Advanced or Metastatic Urothelial Cancer
- Radiation With Concurrent Capecitabine and Mitomycin-C for Muscle-Invasive Bladder Cancer
- Practical Issues With Use of Edrafitinib in Urothelial Carcinoma